Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.030
-0.010 (-0.96%)
Jan 23, 2026, 12:14 PM EST - Market open
Cardiol Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
18
Market Cap
101.01M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 78.76K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organigram Global | 186.08M |
| Assertio Holdings | 137.35M |
| Anika Therapeutics | 112.81M |
| Rockwell Medical | 75.58M |
| InterCure | 72.16M |
| Cumberland Pharmaceuticals | 41.28M |
| Alpha Teknova | 39.80M |
| Zhengye Biotechnology Holding | 21.46M |
CRDL News
- 3 hours ago - Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million - Newsfile Corp
- 7 days ago - Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - Newsfile Corp
- 7 days ago - Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - Newsfile Corp
- 10 days ago - Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Newsfile Corp
- 7 weeks ago - New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions - Newsfile Corp
- 2 months ago - Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 - Newsfile Corp
- 2 months ago - Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases - Newsfile Corp
- 3 months ago - Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027 - Newsfile Corp